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Background: Stable expression of transgenes is an important technique to analyze gene function. Various drug
resistance genes, such as neo, pac, hph, zeo, bsd, and hisD, have been equally used as selection markers to isolate a
transfectant without considering their dose-dependent characters.
Results: We quantitatively measured the variation of transgene expression levels in mouse embryonic stem (mES)
cells, using a series of bi-cistronic expression vectors that contain Egfp expression cassette linked to each drug
resistant gene via IRES with titration of the selective drugs, and found that the transgene expression levels achieved
in each system with this vector design are in order, in which pac and zeo show sharp selection of transfectants
with homogenously high expression levels. We also showed the importance of the choice of the drug selection
system in gene-trap or gene targeting according to this order.
Conclusions: The results of the present study clearly demonstrated that an appropriate choice of the drug
resistance gene(s) is critical for a proper design of the experimental strategy.
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The introduction of exogenous transgene cassettes into
culture cells to direct their expressions is an important
strategy in molecular biology to analyze the functions of
the genes. However, a simple introduction of the DNA
fragment into cells by either electroporation or lipofection
results in its stable integration into the genome of the host
cells only at a low frequency. Therefore, it is always requi-
red to select the cells carrying the integrated copies of the
transgenes by using dominant selection markers. The
combinations of the antibiotics that kill the mammalian
cells and the genes that establish the resistance against
them have been preferentially applied for this purpose:
such as neomycin phosphotransferase II from transposon
Tn5 (designated as neo in this paper) against the neomycin
derivative G418, puromycin N-acetyltransferase from* Correspondence: niwa@cdb.riken.jp
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reproduction in any medium, provided the orStreptomyces alboniger (pac) against puromycin, hygro-
mycin B phosphotransferase from Escherichia coli (hph)
aginst hygromycin B, Streptoalloteichus hindustanus ble
(Sh ble: designated as zeo in this paper) against the bleo-
mycin derivative zeocin, blasticidin S deaminase from
Aspergillus terreus (bsd) against blasticidin S, and histidi-
nol dehydrogenase from Salmonella typhimurium (hisD)
against histidinol [1-6]. These drugs and the resistance
genes have equally been regarded as dominant selection
markers that reflect the introduction of the transgenes
into mammalian cells. Transfection of drug resistance
genes together with transgenes, each in separate expression
cassette, to obtain stable transfectants has been a com-
monly used method. However, in this strategy, the drug
resistance does not always appropriately reflect the expres-
sion level of the transgene because generally the stable
expression levels of exogenous expression cassettes are
highly sensitive to thier sites of integration, as a result of
the local chromatin environment when the transgenes are
randomly integrated into the host genome [7], which affect
the expression levels of the drug resistance gene cassette
and the transgene cassette separately.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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drug resistance gene using an internal ribosome entry
site (IRES) is able to confer a tight correlation between
the transgene expression and the drug resistance be-
cause the IRES-mediated cap-independent translation
ensures parallel expressions of the transgene and the
drug resistance gene [8]. This vector design is particu-
larly important to drive transgene expressions in mouse
embryonic stem (mES) cells since the silencing effect to
the stably integrated transgene cassette is problematic in
these cells [9]. In this vector design, the expression levels
of the transgenes depend on the threshold expression
levels of the drug resistance genes that confer the
survival of the transfectants in the presence of the drugs.
The expression levels of some transgenes can also
possess unique thresholds based on their effect on cell
viability. The combination of the effect of the transgene
with the range of selection generated by the antibiotic
resistance marker can produce a narrow expression
range that can mimic the physiological function range of
expression. Therefore, a proper choice of drug resistance
genes is important to achieve the optimal range of trans-
gene expression levels.
Here we demonstrated the parallel comparison of the
kinetics among each drug selection system determined
by the expression levels from the IRES-based expression
vectors. We found obvious differences in their kinetics
and the impact on various experimental situations.
Results
Kinetics of the drug-selection systems in the IRES-based
expression vectors
To evaluate the kinetics of the bi-cistronic expression
vectors carrying various drug resistance genes in mES
cells, we constructed a bi-cistronic expression vector
system using enhanced green fluorescent protein (Egfp) as
an indicator of the expression level and drug resistance
genes under the control of the IRES from encephalomyo-
carditis virus (EMCV) driven by the CAG expression unit
[10] (Figure 1A). To apply comparable selection pressures
in different drug-selection systems, we first determined
the minimal doses of each drugs to kill mES cells by serial
titrations (Figure 1B). We determined the minimal doses
as killing more than 93% of mES cells at low cell density
(1×103 cells per 90 mm dish) within 6 days, indicated with
asterisks (Figure 1B). Each vector, that is, pCAG-Egfp-
IRES-neo, -hph, -zeo, -hisD, -bsd, and -pac, was transfected
independently into mES cells via random integration into
the genome by electroporation, and the transfected cells
were seeded at high density (1×106 cells per 90 mm dish)
and cultured in the presence of each drug at the concen-
trations of the minimal doses, twice higher or three times
higher, from the next day. After the selection for 7 days,
cells were harvested and seeded on new plates followed bythe culture with the same concentrations of the drugs.
Then the expression levels of the transgenes in the
proliferated cells were estimated by the intensities of the
fluorescence measured by flow-cytometry (Figure 1C) and
the Egfp-positive proportions were scored (Figure 1D).
Selection by neo showed broad and lower levels of fluores-
cence even at the highest dose (3 times higher than the
minimal dose), in which less than 50% of the selected cells
were diagnosed as Egfp-positive and strong positive cells
expressing Egfp more than the relative intensity value of
103 were merely observed. This situation may refer to the
original distribution of the Egfp expression under the
CAG unit at different integration sites in the genome.
Similar tendency was observed for the selection with hph,
hisD and bsd although the hisD selection gave higher
levels of Egfp expressions and the bsd selection conferred
higher proportion of the Egfp-positive cells than the neo
selection. In contrast, selection with pac and zeo gave high
proportion of Egfp-positive cells with high levels of
fluorescent signals, indicating the enrichment of the trans-
fectants expressing high levels of the transgene. This is
not due to the application of the high doses of drugs be-
cause once the selection systems started to work at the
minimal dose at high density culture condition, which was
twice of the minimal doses we determined in the pilot ex-
periments at low density culture condition, both pac and
zeo selection systems gave the sharp enrichment of high
expressants. Therefore, we suppose that this observation
reflects the different threshold expression levels of the
drug resistant genes to confer the drug-resistant pheno-
types in mES cells. Pac and zeo require higher levels of
expression to support the proliferation in the presence of
the lethal amount of drugs than others, which allowed us
to obtain the transfectants with homogenously high levels
of transgene expression. These evidences accorded to our
experiences that zeo and pac efficiently worked to select
mES cell lines expressing fluorescent markers ubiquitously
and strongly in chimeric embryos [11], and that neo gave
higher numbers of LIF-independent colonies than pac
when applied to select drive the expression of Tbx3
transgene, of which the expression at high level is toxic in
mES cells [12].
Generation of new fusion genes of fluorescent markers
and drug-resistant genes
If the modulation of the transgene expression levels by
different drug concentration with the bi-cistronic expres-
sion vector enables us the precise control of transgene
expression, the monitoring of the expression levels of the
drug resistance genes in living cells will be ideal. The func-
tional fusion genes of Egfp and neo, and Egfp and hph have
already been reported [13]. Here we made two novel
chimeric selection markers composed of drug resistance
genes and fluorescent markers and tested their functions.
Figure 1 Expression levels of the transgenes from the stably integrated bi-cistronic transgene cassettes with various drug selection
systems. (A) Design of the bi-cistronic expression vectors containing the drug resistance genes. The drug resistance genes for G418 (neo),
puromycin (pac), hygromycin B (hph), zeocin (zeo), blasticidin S (bsd), and histidinol (hisD) were fused to EMCV-IRES and placed downstream of
Egfp under the control of the CAG expression unit [10]. (B) Determination of the minimal concentrations of the drugs. The D3 mES were seeded
at low cell density (1000 cells per 90 mm dish) with various concentrations of drugs in triplicate, and the cell numbers were counted. The relative
number of the cells to that obtained without the drug, which was set at 1.0, are shown. Asterisks show the doses of 1× of the selection in FACS
analyses, by which more than 93% of the wild-type mES cells were killed. (C) The FACS analyses for the EGFP expression levels. In these FACS
analyses, the EGFP expression level (FL1) under the selection with the minimal concentration (1×, green line), twice higher than the minimal
concentration (2×, red line) and three times higher than the minimal concentration (3×, blue line) were analyzed by flow cytometry using
FACSCalibur (BD). Blue filled peaks indicate the signals from wild-type mES cells. (D) Quantification of the relative cell numbers expressing EGFP.
The proportions within M1 indicated in C are shown.
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that both hisDsRed (hisD + DsRedT4) and pacEgfp
(pac + Egfp) are bi-functional as drug resistance markers
comparable to the wild-type genes and as fluorescent
markers (Figure 2A, E): The fusion genes worked as drug-
resistant genes as efficiently as the wild-type genes since
they gave comparable numbers of the drug-resistant
colonies (Figure 2B, F); They also worked as the fluorescent
markers that were expressed at the levels correlating to the
transgenes placed at the upstream (Figure 2C, D, G, H).
Therefore, these fusion genes will be useful for monitoring
the gene expression levels in the stable transfectants.Application of the drug-resistant systems to gene targeting
The IRES-mediated drug resistance gene cassettes are
also useful for the gene targeting since this strategy is
able to enrich the homologous recombinants [14]. When
the promoter-less knockout vectors carrying the IRES-
mediated drug resistance gene cassettes are integrated
into the genome via random insertion, only the clones in
which the IRES-mediated drug resistance gene cassettes
are accidentally inserted into the genes and driven by
the upstream promoter will survive, whereas all homolo-
gous recombinants are alive if the transcription levels of
the IRES-mediated drug resistance gene cassettes reach
Figure 2 Bi-functional chimeric proteins of drug resistance genes and fluorescent markers. (A, E) Design of the vectors to test the
functions of the fusion proteins driven by the CAG promoter. All constructs were electroporated into D3 mES cells, and the transfectants were
selected with the standard concentrations of puromycin (A) or histidinol (D) as in Figure 1. (B, F) The numbers of the primary colonies from pac
(red) and pacEGFP (green) after puromycin selection (B), and hisD (green) and hisDsRed (red) after histidinol selection. Comparable numbers of
drug resistant colonies were obtained in both cases by the fusion constructs. (C) FACS analyses of the transfectants with pac vectors. EGFP
fluolescence could be detected in the transfectant containing pacEGFP (green line) but not pac (red line) (upper panel: FL1). Levels of DsRed
fluorescence in ES cells with pacEGFP (green line) were comparable to that with pac (red line) (lower panel: FL2). (D) Correlation between the
expression levels of DsRed and Egfp from CAG-DsRed-IRES-pac-pA (upper) and CAG-DsRed-IRES-pacEGFP-pA (lower). (G) FACS analyses of the
transfectants with hisD vectors. Levels of EGFP fluorescence in mES cells with hisDsRed (red line) were comparable to that with hisD (green line)
(upper panel: FL1). DsRed fluolescence could be detected in the transfectant containing hisDsRed (red line) but not hisD (green line) (lower panel: FL2).
(H) Correlation between the expression levels of DsRed and Egfp from CAG-EGFP-IRES-hisD-pA (upper) and CAG-EGFP-IRES-hisDsRed-pA (lower).
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evaluate the expression levels achieved by these selection
systems in comparison to the endogenous genes, we
next tested their functions by the gene-trap method [15].
We placed the drug resistance genes fused to IRES
(Figure 3A) downstream of the splice acceptor and in-
troduced them into the host cells. With the pac selection
system, we obtained very few drug-resistant colonies—less than 10% of the number obtained with the neo
selection system (Figure 3B)—indicating that the threshold
expression level of the pac selection system could be
achieved only with strong endogenous promoters.
Previous applications of the neo selection system to the
gene-trap strategy in mES cells revealed that ~15,000
of ~20,000 genes expressed in mES cells could be trapped
[16], indicating that this selection system can work under
Figure 3 Comparison of the efficiency of gene trap with
different drug selection systems. (A) Design of the gene trap
vectors containing the different drug resistance genes. The drug
resistance genes were fused to EMCV-IRES and placed downstream
of the splice acceptor (SA) of Engrailed (En)-2 gene [15]. (B) The
numbers of drug-resistant colonies in gene-trap screening were
counted in each drug selection. Columns and bars represent
average colony numbers and standard error means (s.e.m.) among
the triplicate per 2 × 107 mES cells transfected with 100 μg of each
promoter trap vector, respectively.
Table 1 The expression levels of the genes targeted by





Zfp42 4.8854 pac, hph, bsd Toyooka et al., 2008 [18]
Masui et al., 2008 [11]
Socs3 4.4746 pac (this paper)
Pou5f1 4.4563 pac, neo, zeo Nichols et al., 1998 [19]
hph, bsd Toyooka et al., 2008 [18]
Klf4 4.2232 pac (unpublished)
Sox2 4.2167 hph, hisD Masui et al., 2007 [20]
Sema4d 3.8042 neo Taniguchi et al., 2009 [21]
Nrp2 3.6699 neo Takashima et al., 2002 [22]
Cry1 3.5175 neo Vitaterna et al., 1999 [23]
Rad18 3.4387 neo Tateishi et al., 2003 [24]
Cry2 3.2127 neo Vitaterna et al., 1999 [23]
Esrrb 2.0747 neo Martello et al, 2012 [17]
Nrp1 1.6905 neo Takashima et al., 2002 [22]
*Microarray data of 50 ES cell lines (Nishiyama et al., [25]). Hprt: 4.9305,
Gapdh: 5.2380, Actb: 5.2452.
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tional activities. We succeeded to obtain homologous
recombinants for Nrp1, Nrp2, Sema4d, Cry1, Cry2 and
Rad18 using the promoter-less targeting vector with neo at
high efficiency (>10% of G418 resistant clones), confirming
the high sensitivity of the neo selection system because the
expression levels of these neuronal and housekeeping
genes are moderate or low in ES cells (Table 1). In contrast,
the promoter-less targeting vector with pac looks only
applicable for the genes expressed at high levels, such as
Zfp42 and Oct3/4, although the knockout efficiency is high
(>50% of puromycin resistant clones). In the case of
Estrogen-related receptor β (Esrrb), we got the homologous
recombinants using the promoter-less targeting vector
with neo but not with pac, indicating the difference of their
threshold levels as well as the importance of their choice
([17] and Sugimoto, Adachi and Niwa, unpublished). Other
markers are also applicable for the promoter-less targeting
vectors like in the cases of Zfp42, Oct3/4 and Sox2, which
are all expressed at high levels (Table 1).
Efficient selection of the gene conversion event by pac
Sensitive dosage effect of the puromycin selection
system could be advantageous for the tight selection of
the expression level of pac. To select the homozygous
mutant mES cells spontaneously appearing in the het-
erozygous pools via gene conversion, the efficientselection of the cells expressing two copies of the selec-
tion marker genes from those expressing one copy is
required. The neo system was reported to be applicable
for such selection, but the efficiency is not so high in
general as originally reported [26]. We previously ap-
plied the puromycin selection system in the same way to
get the homozygous mES cells for the Zfp42 knockout
allele, which resulted in the 100% efficiency of the selec-
tion (4 in 4 clones analyzed) [11]. Here we tested the
general applicability of this strategy in heterozygous
mES cells carrying the promoter-less pac cassette. In the
case of the heterozygous mES cells for the Socs3 knock-
out allele, the titration of puromycin concentration
determined the maximal dose allowing the survival of
the majority of the heterozygotes at 4 μg/ml, and the
high-dose (6 μg/ml) puromycin selection resulted in the
100% efficiency of the homozygous mutant selection
(46 in 46 clones analyzed; Figure 4). Similarly, in the
case of the heterozygous mES cells for the floxed Klf4
allele, the high-dose (6 μg/ml) puromycin selection
resulted in 60% efficiency of the homozygous mutant
selection (12 in 20 clones analyzed; data not shown).
These data indicated that the tight dosage-dependency
of the puromycin selection system is suitable for this
strategy.
Discussion
The drug resistance genes described here can be used
simultaneously for multiple transgene expression and
gene targeting in mES cells. There is no interference
Figure 4 Generation of mES cells homozygous for the Socs3 knock-out allele by high-dose puromycin selection. (A) Strategy for the
generation of Socs3-KO ES cells. The schematic maps of the Socs3 allele (top), the KO vector carrying the Cherry-IRES-pac-pA cassette (middle),
and the KO allele generated by homologous recombination (bottom). The PCR with the primers set at the 5′ external genome and the open
reading frame (ORF) in the second exon provides the polymorphism between the wild-type and mutant alleles, 2.1 kb and 4.8 kb, respectively.
(B) Sensitivity of the heterozygous clone to various concentration of puromycin. Most of the cells were killed by 3.0 μg/ml of puromycin for
5 days. (C) PCR analysis of the genotypes of the clones selected by 6 μg/ml of puromycin from the heterozygotes. All clones possess the mutant
allele only, indicating that they are homozygotes for the Socs3-KO allele.
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we succeeded to obtain mES cells carrying multiple
drug-resistance genes in various combinations [20,27].
Here we described the different kinetics of the drug
selection systems pac, zeo, hph, hisD, bsd and neo. Pac
and zeo require high levels of expression to confer the
proper drug resistance to mES cells, whereas neo estab-
lishes the resistance to G418 with minimal expression
level in mES cells.
In the conventional transgene expression strategy, the
drug resistant genes were driven under the control of
strong viral enhancer/promoters derived from simian
virus 40 and human cytomegalovirus. However, sepa-
ration of the expression units of the transgene and the
drug-resistant genes failed to ensure the transgene
expression in the drug-resistant cells and it was required
to screen a large number of drug-resistant clones to
obtain the stable transfectants with ideal expression
levels. The IRES-mediated bi-cistronic expression vector
directs the expression of the transgene and the drug-
resistant gene from the same promoter, in which the
drug selection always confirms the expression of thetransgene. If we apply the rule we identified in this
report, it is possible to design an expression vector with
an ideal expression level of the transgene by a proper
choice of the drug selection system. To obtain the
homogenous expression of the fluorescent markers in
mES cells, pac and zeo are recommended as we succeeded
previously [11,20]. However, when a moderate or low level
of expression is ideal like in the cases of tetracycline-
dependent transcriptional activator tTA/rtTA, of which
the expression at a high level is toxic for mES cells (Niwa,
unpublished), and Tbx3 [12], neo is the first choice.
We recently reported the function of Esrrb as a target
of glycogen synthase kinase-3 (Gsk3)-Tcf3 pathway [17].
In this report we first applied the bi-cistronic expression
vector with CAG and IRES-hph to direct the expression
of Esrrb in mES cells, resulting in 6–8 fold higher
expression of Esrrb transgene than the endogenous
levels. Since this situation creates the possibility of
neomorphic effects, we switched to the expression
vector with IRES-neo and succeeded to confirm that the
constitutive expression of the exogenous Esrrb at endo-
genous levels is sufficient to sustain self-renewal of mES
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good example demonstrating the importance of the
choice of a proper drug selection system to obtain
appropriate levels of transgene expression. Well-designed
strategy for transgene expression will provide clear results
in cell biological analyses.
Conclusions
The expression levels of the transgenes using the bi-
cistronic expression vectors depend on the drug selection
systems. Appropriate choices of the systems will give clean
results. This is also applicable to the gene targeting with
bi-cistronic durg-resistant genes. The principle shown
here in mES cells should be applicable to mouse induced
pluripotent stem (iPS) cells directly and most likely to
human ES cells after modification.
Methods
Plasmid constructions
Initial Methionine of all drug resistance genes in Egfp
expression vectors were fused in frame to ATG sequence
of the NcoI site in 3′ terminus of EMCV-IRES sequence
derived from pCITE-1 (Novagen). pCAG-IP and pCAG-
IZ plasmid was constructed for puromycin and zeocin
selection as described [9,28]. pCAG-IB was constructed
by replacing the NcoI-XbaI fragment in pCAG-IZ with
the BsaI-SpeI fragment containing the bsd gene derived
from pUC-SV-BSD (Funakoshi). hisD ORF was amplified
from pAGHisD plasmid (a gift from S. Takeda, Kyoto
university) by PCR method with sense primer fused to
BspHI recognition site and antisense primer fused to
XbaI site and exchanged NcoI and XbaI fragment of
pGTIRESβgeopA [14], resulting pGTIRESHisDpA. pCAG-
ID was made by replacement of KpnI-BamHI fragment
between the pGTIRESHisD and pCAG-IP. PvuI-MscI frag-
ment of pBR322 was ligated to blunted BamHI and PvuI
digested pCAG-IP, resulting pBRCAG-IP. pGTIRESHygropA
was made by exchanging BspHI-BglII hygro-PGKpA frag-
ment from pSP72-tkphygropA with NcoI-BamHI fragment
of pGTIRESβgeopA in which BamHI and BstXI sites within
PGKpA are disrupted. pCAG-IH was constructed by
exchanging BamHI-KpnI fragment between pBRCAG-IP
and pGTIRESHygropA. The puromycin resistance gene of
pBRCAG-IP was also exchanged with PCR fragment amp-
lified from pMC1-neo-pA (Stratagene) with BspHI site
attached sense primer and both BamHI site and SV40
polyA attached antisense primer, resulting pCAG-IN.
pPyCAGIHisDsRedT4 was made by fusing of DsRedT4
[29] open reading frame (ORF) to C-terminus of hisD
gene linked with 5′-gagcaagcaagatcgaccaccatg-3′ sequen-
ce. The Egfp fragment with XhoI and NotI site obtained
from pEGFP-N1 (Clonetech) by PCR was inserted between
XhoI and NotI site upstream of IRES in each expression
vector backbone, pCAG-IP, -IZ, -ID, -IH, -IB, and –IN,examined for puromycin, zeocin, histidinol, Hygromycin B,
blasticisin S, and G418 selection, respectively. pCAG-
IpacEGFP was constructed by replacement pac fragment
of pCAG-IP with pacEGFP fusion fragment ligated bet-
ween SalI/NotI digested Egfp fragment from pEGFP-N1
and pac fragment amplified by PCR (sense: 5′-CCTCAT
GACCGAGTACAAGCCCA-‘3 antisense: 5′-CGGATCCG
GCACCGGGCTTGCGGGTCAT-3′) that was digested
with BspHI/BamHI, linked between partially filled BamHI
and SalI site. hisDsRedT4 ORF was inserted between XhoI
and NotI site of pCAG-IP and –IpacEGFP. Full sequence
information’s of all expression vectors are available on
our web site (http://www.cdb.riken.jp/pcs/protocol/vector/
vector_top.html).
Cell culture and electroporation
D3, E14tg2a and EB3 ES cells were maintained in the
absence of feeder cells in Glasgow minimal essential
medium (GMEM) supplemented with 10% fetal calf
serum, 10-4 M 2-mercaptoethanol, and 1000 unit/ml of
LIF at normal condition 37°C, 5% CO2 [30]. 2 × 107 ES
cells were electroporated with 30 μg of linearized plasmid
DNA at 800 V and 3 μF in a 0.4 cm cuvette using a Gene-
Pulser (Bio-Rad) and then cultured in the presence of the
drugs for selection, Puromycin (Nacalai tesque) Zeocin
(Invivogen), Hygromycin B (HygroGold, Invivogen), L-
Histidinol (Sigma), Blasticidin S (Invivogen) and G418
(Nacalai tesque), at indicated concentrations. Colonies were
identified by Leishman (SIGMA) staining, and counted.
Flow cytometric analysis
Transfectants grown in the presence of each drug con-
centrations were harvested and 10.000 data points were
collected for each sample in flow cytometry, using
FACSCALIBUR (Becton Dickinson). Data were analysed
using CellQuest Pro Software ver.5.2 (Becton Dickinson).
Gene targeting of Socs3
Genomic DNA sequences were amplified using the
primers 5′- ataaatCGatGGCGGCTCTAACTCTGACTC
TACACTC-3′ and 5′- ttaagctTGGCGCACGGAGCCA
GCGTGGATCTG-3′ (for the left arm of the KO con-
struct); and 5′- CCGGGATcCGGTAGCGGCCGCTGT
GCGGAG-3′ and 5′- CAGAGCTCgtcgaCTCCTGTCT
GTACAGAAGGAAAGAGAGAG-3′ (for the right arm
of the KO construct). Amplified PCR products were
cloned into pBR-blue vecotor. The 1.0 kb ClaI (in pri-
mer)–NotI (in genomic DNA) fragment from the left arm
and the 3.0 kb NotI (in genomic DNA)–SacI (in primer)
fragment were cloned into pBR-MC1DTApA. The NotI
site was used to clone the marker gene cassette dCherry-
IRES-pac-pA. 1 × 107 EB3 ES cells were electroporated
with 100 μg of plasmid DNA linealized by XhoI. From the
next day, these transfectants were selected with 1.5 μg/ml
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were picked, expanded and analyzed their genotype by
PCR using the primers 5′- CAGTCCTCCTAGTCGA
CATTCCTTCTC-3′ 5′- ttaagctTGGCGCACGGAGCCA
GCGTGGATCTG-3′ with KOD-Fx (Toyobo) that amplify
2.1 kb fragment from the wild-type allele and 4.8 kb frag-
ment from the targeted allele. One of three homologous
recombinants (sKO2) was examined for their ability to
survive higher concentration of puromycin, and 1 × 106
sKO2 ES cells were selected with 6 μg/ml of puromycin
for 4 days followed by the culture with 1.5 μg/ml of
puromycin for 6 days. About 100 colonies were formed
and 46 clones were picked, expanded and analyzed their
genotype by PCR using the primers shown above.
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